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Summary
Nutritional-pharmacological interactions were studied
in a group of malnourished subjects. Antipyrine was used
to evaluate mixed-function oxidase in man. The results
indicated that the rate of disappearance of antipyrine
from plasma was strongly influenced by the nutritional
status of the individual. The half life of antipyrine was
modified in undernourished subjects and those with
nutritional oedema.
This finding indicates that drug regimens may have to
be adjusted in patients who have antipyrine half lives
that are shorter or longer than normal. Otherwise drug
treatment may be inadequate or, in patients with im-
paired microsomal enzyme activity, potentially dan-
gerous.
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Patients and methods
Four groups of subjects were chosen for the study. Seven healthy
male laboratory workers volunteered to serve as controls (group 1).
They did not smoke or drink. Eight other healthy men who smoked
were also studied (group 2). Thirteen undernourished men with
weight deficits of varying degrees formed group 3. Fifteen men
suffering from nutritional oedema-a severe manifestation of protein
calorie deficiency-formed group 4. The oedema in these subjects
was due to inadequate food intake and consequent hypoalbuminaemia.
All subjects with nutritional oedema received frusemide, a diuretic,
before the investigation to remove as much extracellular fluid as
possible. Frusemide was given for only three days.
After an overnight fast antipyrine, 18 mg/kg body weight, was
given by mouth with 300 ml of water. No food was permitted for
three hours thereafter to ensure complete absorption of the drug.
Blood was collected four, six, nine, and 12 hours after drug adminis-
tration and the samples were assayed for antipyrine.6 Log concentra-
tions versus time were plotted and elimination rate constants and half
times were calculated by the method of least squares. The pharma-
cokinetic data were calculated by regression analysis of the log of the
plasma concentrations with respect to time in each group. The
statistical analysis was carried out by analysis of covariance technique.
Introduction
The nutritional status of an individual may affect his drug
metabolism. The activity of the drug metabolising enzymes
located in the microsomal fraction of the liver is important in
determining blood and tissue concentrations of drugs. Many
reports suggest that malnutrition, which is prevalent in the
developing countries, may lead to changes in the activity of
mixed-function oxidases.1 2 Most of these studies have been
done in animals, however, and studies evaluating the capacity
of malnourished human subjects to metabolise drugs are scanty.
Poskitt3 recently reviewed studies on the clinical problems
related to the use of drugs in malnutrition. Abnormalities in the
structure and function of the endoplasmic reticulum, consequent
on malnutrition, may be expected to change drug metabolism
in man. We have already reported that the plasma half life of
tetracycline is significantly changed in undernourished people.4
But tetracycline is an antibiotic that does not undergo biotrans-
formation. We therefore considered it possible that drugs that
are metabolised by the microsomal enzymes may behave
differently in malnourished subjects.
We evaluated the microsomal enzyme systems in man using
antipyrine half life as an index of drug metabolism. Antipyrine
is widely used to predict the metabolism of drugs in man, since
it is rapidly and almost completely absorbed from the gastro-
intestinal tract, is slowly metabolised (60/ per hour), and only
the major metabolite-4-hydroxy antipyrine-is excreted in
urine.5 Also, less than 10% of the parent drug is bound to plasma
proteins, and hence the kinetics are not likely to be seriously
affected by changes in plasma protein concentrations.
Results
The anthropometric data and serum albumin concentrations are
indicated in table I. The mean weight in the controls was 58-0 kg,
whereas mean weights in the malnourished subjects in groups 3 and 4
were 42 kg and 39 kg respectively. The heights of the subjects were
similar, thus modifying the weight:height ratio. In normal subjects
the ratio was over 0 20. In the undernourished subjects and those with
nutrition oedema it was only 0-15, indicating the considerable weight
deficit. Sirnilarly, serum albumin concentrations were significantly
different in the control and experimental groups, the patients with
nutritional oedema having the lowest concentrations.
TABLE I-Mean (+ SE) body weight, height, weight:height ratio, and serum
albumin concentration
No of
Group subjects
1 7
2 8
3 13
4 15
Weight
(kg)
58-0 ± 3-63
58-1 ±2-08
41-9 ±1-80
38-6±1-76
-1-
Height
(cm)
164-8±1-26
167-6 ±2-25
162-4 ± 2-65
164-0 ±3-88
Weight
x 100
height2
0-22 ±0-013
0-21 ±i0010
0-16 ±0005
0-15 ±0-006
-1-
Serum
albumin
(gl)
36-7 ± 0-91
37-5 ±0-87
24-5±0 11
20 4±0-123
For weight, weight:height, and serum albumin, group 1 v 2: NS; group 1 v 3:
P <0-001; group 1 v 4: P <O0OO1; group 2 v 3: P <OO01; group 2 v 4: P <0001.
For serum albumin, group 3 v 4: P<005. Differences in height were not significant.
Pharmacokinetic data are shown in table II and fig 1. The extra-
polated plasma concentrations of antipyrine at 0 hour were similar in
all groups (table II). The rate of decline of antipyrine concentrations
in plasma, as indicated by the regression coefficient, was significantly
different between the groups. The concentration declined faster in
control smokers than in control non-smokers. Similarly, the regression
coefficient was significantly lower in undermourished subjects than in
controls who did not smoke, but the decline was similar to that seen
in smokers. The half life calculated from these regression equations
indicated that the half life was 11-22 hours in normal non-smokers,
and 8 60 hours in undemourished people. In patients with nutritional
oedema, the regression coefficient and half life were similar to
those of normal non-smokers but significantly different from those
of smokers and undernourished subjects. The adjusted mean con-
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TABLE II-Pharmokinetic data on antipyrine: concentration at 0 hour, regression coefficient, and plasma half life
Plasma Standard Correlation
Group antipyrine Regression coefficient error of Half life Adjusted mean concentration* coefficient
at 0 hour regression (hours) (,umol/l) (serum levelt([tmol/l) coefficient v time)
1 6-44 - 0-0268 0-001752 11-22
- 3-99i _ 0-80330261 p<O05 1 p<0.05 P<O051
2 639 - 00337J IP<Ol1 0001383 894J P<005 359 P<OO11 07293
3 6-48 - 0O03501 I 0-002942 8o0 - 3-48 L 0-7223
P <0-001 P <0-001 P <0-001
4 6 18 - 0 0235J 0 002230 12 82 4 17 0 8195
*At mean time 7-7641 hours. *P <0-001 for each correlation coefficient.
Conversion: SI to traditional units-Antipyrine: 1 ,mol/1 0 188 ,ug/ml.
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FIG 1-Rate of decline of plasma antipyrine concentrations.
Conversion: SI to traditional units-Antipyrine: 1 ,umol/l
0 188 /sg/ml.
centrations at the mean time of 7 76 hours were significantly different
in the four groups.
The rate of decline of antipyrine in plasma was about 6 2% per
hour in normal non-smokers, 7-81"/hour in smokers, about 9%0/hour in
undernourished subjects, and 570 0/hour in patients with nutritional
oedema. While analysing the data pooled variations between groups
were taken into consideration and the differences between indi-
viduals (probably genetic) were not excluded from the total variation.
Fig 2 shows antipyrine half lives in each subject. The variation in
non-smokers was higher than that in either smokers or under-
nourished subjects. The half life in those with nutritional oedema
varied from 7-55 hours to 22-62 hours. Most of the patients with
nutritional oedema had prolonged half lives compared with the mean
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FIG 2-Antipyrine half life in each subject studied.
half life in normal subjects (11-22 hours) or undernourished subjects
(8-6 hours). Four of the 15 subjects had a half life of over 16 hours,
which was the highest value we encountered in the controls. The
mean half life in patients with nutritional oedema was, however,
comparable to that of normal subjects.
Discussion
There is no general biochemical test to detect slow drug
metabolisers. The normal laboratory tests used to assess liver
function are of little value in predicting the capacity of an indi-
vidual to metabolise drugs. The current trend in drug treatment
is towards fitting treatment to the individual, and it is therefore
essential to study the kinetics of drug elimination. An effective
regimen may then be designed.7 We therefore attempted to
determine the capacity of the liver in malnourished subjects to
handle drugs.
The liver is the major organ responsible for drug metabolism
and consequently for drug disposition and elimination. Hence
hepatic disease obviously affects drug kinetics.8 The clinical
implications of such changes are obvious. Vessel et a19 have
shown that there is interindividual variation in drug metabolism,
as indicated by antipyrine and phenylbutazone metabolism. Our
results confirm their finding. Despite individual variations,
however, there were significant differences between the groups
we studied.
Smokers clear antipyrine faster than non-smokers. Both
nicotine and alcohol stimulate the microsomal enzymes.10
Recently Vestel et all' showed that caffeine and cigarette use
are positively correlated with the rate of antipyrine metabolism
in human subjects. Our data confirm this finding. Drug metabol-
ism seems to be about 15-200o faster in smokers, probably
because of enzyme induction by nicotine. The half life of
antipyrine was also short in our undernourished subjects,
who were smokers and drank alcohol. Some of the subjects in
this group were agricultural labourers, and careful questioning
disclosed that some were exposed to pesticides as well. Kolmodin
et all showed that the plasma half life of antipyrine in workers
exposed to chlorinated hydrocarbons is significantly low. Thus
the microsomal enzymes in our undernourished subjects
seemed to be in an induced state. Undernutrition itself might
also have acted as a stress and induced the enzymes. Basu et al"
have shown that restricted feeding of animals for 14-20 days
results in an induction of microsomal enzymes, and Mgbodile14
has shown increased deoxycorticosterone concentrations in
semi-starved rats.
On the other hand, over half the subjects with severe protein
calorie malnutrition had half lives prolonged by 12-13%, and in
four the half lives were prolonged by 44-88%. In patients with
liver disorders drugs like antipyrine, acetaminophen, chlor-
amphenicol, and phenylbutazone have a prolonged half life.8
But although fatty infiltration and hepatic dysfunction are
characteristic features in children with kwashiorkor, hepatic
involvement is minimal in adults with nutritional oedema.'5
Involvement of the endoplasmic reticulum and its consequences
cannot, however, be ruled out.
Controls Undernourished Patients with(smokers) subjects nutritional
oedema
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The half life of antipyrine reflects the metabolic capacity of
the hepatocytes and is not influenced by plasma protein binding
or hepatic drug delivery rate. Therefore the antipyrine clearance
rates in our subjects indicated each individual's capacity to
metabolise drugs.
Although a diuretic had been given to the patients with
nutritional oedema before the study, some degree of expansion
of the extracellular fluid volume remained. Nevertheless,
Reidenberg et a116 have shown that the metabolism of antipyrine
and tolbutamide is not changed in obese fasting subjects
despite significant changes in body water. The prolonged half
life seen in patients with nutritional oedema was therefore
unlikely to have been due to changes in body water. This view
was also supported by the observations that relative volume
distribution was similar in all the groups investigated.
These changes in the metabolism of antipyrine in mal-
nourished subjects indicate that in certain conditions drug
regimens may have to be changed. A reduction in half life may
call for more frequent administration of drugs. On the other
hand, if microsomal enzyme activity is impaired, and the half
life prolonged, patients may be at a greater risk of accumulating
potent drugs.
We thank Dr S G Srikantia, Director of the National Institute of
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Controlled trial of active immunotherapy in management of
stage IIB malignant melanoma
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Summary
The prognosis for patients who undergo surgery for
stage HB malignant melanoma is poor. Animnal studies
have suggested that BCG and tumour celi vaccines given
together may provide effective immunotherapy. To assess
the effectiveness of this treatment 15 patients with stage
IIB malignant melanoma who had had their tumour
excised were studied. Seven were treated conservatively,
and eight were vaccinated with BCG and autologous
irradiated cells. Three vaccinated patients suffered
widespread recurrence within three months. All four
vaccinated patients who suffered a recurrence within the
first year died, while none of the three controls with
recurrent disease died. In view of this alarming trend the
trial was stopped after a year. BCG and the tumour
cells may have enhanced the tumour growth, although
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there was no apparent reason for this. The results of
uncontrolled or unrandomised trials that have suggested
that this treatment is beneficial should be treated with
scepticism.
Introduction
Within two years of operation about three-quarters of all
patients with malignant melanoma who have affected regional
nodes (stage IIB) will have obvious recurrences and over half
will have died.' Results are therefore likely to improve only if
some other treatment can be added to excision.
The demonstration of tumour-associated antigens on mela-
noma cells and of circulating antibodies and cytotoxic lympho-
cytes directed against them in patients with the disease has
suggested that immunotherapy may be useful,2 but there have
been few good controlled clinical trials of such treatment.3
Bacillus Calmette-Guerin (BCG) has been included in the
treatment of malignant melanoma as a non-specific immuno-
stimulant. Intralesional BCG will often produce tumour
regression,4 and intradermal BCG, given repeatedly, may delay
recurrence after surgery5 and augment the response to chemo-
therapy.6 In contrast, specific immunotherapy with irradiated
tumour cells, while increasing cytotoxic antibody production
and the proportion of circulating cytotoxic lymphocytes, has no
apparent effect on the outcome in patients with widespread
disease.7 Nevertheless, animal studies indicate that host
resistance to transplantable tumours is enhanced when BCG and
tumour cell vaccines are given together as contact immuno-
therapy provided that the tumour load is small. This suggests
